BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...12 programs in preclinical development for other rare diseases including Batten disease, retinitis pigmentosa and Darier...
BioCentury | Sep 15, 2017
Financial News

BridgeBio raises $135M round

...is not disclosed. BridgeBio's other subsidiaries house preclinical assets for indications including pantothenate kinase-associated neurodegeneration, Darier...
BioCentury | Sep 13, 2017
Financial News

BridgeBio raises $135M round

...is not disclosed. BridgeBio's other subsidiaries house preclinical assets for indications including pantothenate kinase-associated neurodegeneration, Darier...
BioCentury | Feb 8, 2010
Financial News

Lombard Odier Darier Hentsch & Cie financial update

...World Healthcare Index and will be managed by lead portfolio manager Jim Patricelli. Lombard Odier Darier...
BioCentury | Jan 21, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...BioSciences Inc., a subsidiary of ProMetic Life Sciences Inc.; ProMetic has partnered with Laboratorios Dermatológicos Darier...
BioCentury | Nov 13, 2006
Strategy

Expanding the envelope

...BZ Bank, representing several of its clients, and was supported by existing investors Lombard Odier Darier...
BioCentury | Oct 31, 2006
Financial News

NovImmune raises $46.1 million

...new investor BZ Bank. New investor Pictet Private Equity Investors joined existing investors Lombard Odier Darier...
BioCentury | May 9, 2005
Finance

Ebb & Flow

...dosed outside of the hospital. Other underwriters on the IPO were Julius Baer; Lombard Odier Darier...
BioCentury | May 5, 2005
Financial News

Arpida prices IPO

...proposed range of CHF18-CHF22. The deal was underwritten by Deutsche Bank; Julius Baer; Lombard Odier Darier...
BioCentury | Apr 25, 2005
Finance

Ebb & Flow

...the company at CHF327.4 million ($272.8 million). Underwriters are Deutsche Bank; Julius Baer; Lombard Odier Darier...
Items per page:
1 - 10 of 22
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...12 programs in preclinical development for other rare diseases including Batten disease, retinitis pigmentosa and Darier...
BioCentury | Sep 15, 2017
Financial News

BridgeBio raises $135M round

...is not disclosed. BridgeBio's other subsidiaries house preclinical assets for indications including pantothenate kinase-associated neurodegeneration, Darier...
BioCentury | Sep 13, 2017
Financial News

BridgeBio raises $135M round

...is not disclosed. BridgeBio's other subsidiaries house preclinical assets for indications including pantothenate kinase-associated neurodegeneration, Darier...
BioCentury | Feb 8, 2010
Financial News

Lombard Odier Darier Hentsch & Cie financial update

...World Healthcare Index and will be managed by lead portfolio manager Jim Patricelli. Lombard Odier Darier...
BioCentury | Jan 21, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...BioSciences Inc., a subsidiary of ProMetic Life Sciences Inc.; ProMetic has partnered with Laboratorios Dermatológicos Darier...
BioCentury | Nov 13, 2006
Strategy

Expanding the envelope

...BZ Bank, representing several of its clients, and was supported by existing investors Lombard Odier Darier...
BioCentury | Oct 31, 2006
Financial News

NovImmune raises $46.1 million

...new investor BZ Bank. New investor Pictet Private Equity Investors joined existing investors Lombard Odier Darier...
BioCentury | May 9, 2005
Finance

Ebb & Flow

...dosed outside of the hospital. Other underwriters on the IPO were Julius Baer; Lombard Odier Darier...
BioCentury | May 5, 2005
Financial News

Arpida prices IPO

...proposed range of CHF18-CHF22. The deal was underwritten by Deutsche Bank; Julius Baer; Lombard Odier Darier...
BioCentury | Apr 25, 2005
Finance

Ebb & Flow

...the company at CHF327.4 million ($272.8 million). Underwriters are Deutsche Bank; Julius Baer; Lombard Odier Darier...
Items per page:
1 - 10 of 22